New approach for treating idiopathic pulmonary fibrosis

June 8, 2015, Helmholtz Association of German Research Centres

Researchers at Helmholtz Zentrum München, in collaboration with an international team, have identified a potential novel drug target for idiopathic pulmonary fibrosis, a dangerous chronic lung disease. They elucidated a new mechanism of fibrosis formation that plays an important role in the pathogenesis of the disease. These findings have now been published in the leading scientific journal American Journal of Respiratory and Critical Care Medicine.

Idiopathic pulmonary fibrosis (IPF) is a for which as yet no causal therapy exists. It is, however, known that the lung interstitium – the connective tissue between the air sacs in the lower part of the lung – is affected. There scar tissue consisting mainly of collagen accumulates, thus reducing lung elasticity and gradually impairing lung function. Patients with IPF have an extremely poor prognosis; on average they survive only two or three years after the diagnosis has been made.

Analysis of patient data

Prof. Dr. Oliver Eickelberg and Dr. Claudia Staab-Weijnitz of the Comprehensive Pneumology Center (CPC) at Helmholtz Zentrum München and their colleagues at LMU University Hospital in Munich and Yale University School of Medicine have now discovered a new therapeutic target for IPF. The main focus of their research was to identify causative mechanisms involved in the disease. The researchers analyzed microarray data of samples from German patients and from an IPF cohort of the Lung Tissue Research Consortium in the U.S.

The analysis revealed elevated levels of the protein FKBP10 in the lungs of IPF patients. The researchers hypothesized that if the production or activity of the protein could be inhibited, this might lead to a new therapeutic approach. Further experiments confirmed that knockdown of this protein in IPF fibroblasts diminished the collagen synthesis. "Thus, FKBP10 represents a potential new target molecule for the individualized therapy of IPF," said Claudia Staab-Weijnitz. "In the future, these results could also lead to new therapeutic options for the treatment of other fibrotic diseases."

New ways to understand the disease cause

Eickelberg has made the study of IPF one of his key priority research areas. Together with his team of researchers, he is studying the pathogenic mechanisms with the aim to develop causal therapies – and thus one day to actually cure IPF. In the short term, however, the main focus is on delaying the progression of the disease and alleviating the symptoms. "My foremost objective is to help develop an effective treatment that will completely halt the progression of IPF in the patient," said Eickelberg. "These approaches are best developed in international networks. This cooperative project is a direct result of the research stay of Professor Kaminski (Yale) at the CPC through the support of a Helmholtz International Fellow Award (HIFA)."

"With our translational approach," said Eickelberg, "we want to help alleviate the suffering of patients with ." In the case of IPF, the researchers now want to establish a drug screening assay and begin clinical trials with an FKBP10 inhibitor, an agent to inhibit the production or activity of the FKBP10 protein.

Explore further: Promising new target may treat pulmonary fibrosis

More information: "FK506-binding Protein 10 is a Potential Novel Drug Target for Idiopathic Pulmonary Fibrosis." Am J Respir Crit Care Med. 2015 Jun 3. www.ncbi.nlm.nih.gov/pubmed/26039104

Related Stories

Promising new target may treat pulmonary fibrosis

March 18, 2015
By uncovering the mechanism by which fibrous tissue cells in the lung multiply, researchers at The Saban Research Institute of Children's Hospital Los Angeles (CHLA), along with colleagues in Mexico and Canada, have identified ...

Newly identified biomarkers help predict outcome in idiopathic pulmonary fibrosis

October 2, 2013
A Yale-led study has identified a gene expression profile that can predict outcomes and lead to better treatment for one of the most lethal lung diseases, idiopathic pulmonary fibrosis (IPF). The study appears in Science ...

Idiopathic pulmonary fibrosis cases linked with asbestos exposure

September 9, 2014
A proportion of idiopathic pulmonary fibrosis (IPF) cases may be linked with asbestos exposure, according to the results of a new study. If confirmed, the findings would mean that current treatment strategies need to be altered ...

Reversing the effects of pulmonary fibrosis

September 22, 2014
Yale University researchers are studying a potential new treatment that reverses the effects of pulmonary fibrosis, a respiratory disease in which scars develop in the lungs and severely hamper breathing.

Finding cellular causes of lung-hardening disease

September 17, 2013
(Medical Xpress)—Idiopathic Pulmonary Fibrosis, or IPF, is an incurable lung disease that, over time, turns healthy lung tissue into inflexible scar tissue – hardening the lungs and eventually causing respiratory distress ...

HRCT scans can identify deadly lung disease

February 17, 2014
People who have suspected idiopathic pulmonary fibrosis (IPF) without typical patterns on high resolution computed tomography scans could in future be spared the substantial risks of lung biopsy and be given a confident diagnosis ...

Recommended for you

Fighting a deadly parasite: Scientists devise a method to store Cryptosporidium, aiding vaccine research efforts

September 21, 2018
In May, just before one of the hottest summers on record, the U.S. Centers for Disease Control and Prevention issued a warning about diseases lurking in recreational water facilities like swimming pools and water playgrounds. ...

Scientists make significant discovery in the fight against drug-resistant tuberculosis

September 20, 2018
A team of scientists have identified a naturally occurring antibiotic that may help in the fight against drug-resistant Tuberculosis.

Anti-cancer drugs may hold key to overcoming antimalarial drug resistance

September 20, 2018
Scientists have found a way to boost the efficacy of the world's most powerful antimalarial drug with the help of chemotherapy medicines, according to new research published in the journal Nature Communications.

Affordable Care Act: Study finds surprising gaps in HIV care providers' knowledge

September 20, 2018
A new study has revealed surprising gaps in some HIV medical providers' knowledge of the Affordable Care Act, with more than a quarter of providers surveyed unable to say whether their state had expanded Medicaid.

Preventing a dengue outbreak at the 2020 Summer Olympics

September 20, 2018
In 2014, a dengue outbreak unexpectedly occurred in Tokyo. What does that mean for the 2020 summer Olympics and Paralympics being held in the city? Researchers report this week in PLOS Neglected Tropical Diseases that new ...

Researchers discover influenza virus doesn't replicate equally in all cells

September 19, 2018
The seasonal flu is caused by different subtypes of Influenza A virus and typically leads to the death of half a million people each year. In order to better understand this virus and how it spreads, University of Minnesota ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.